tiprankstipranks
Trending News
More News >
Igm Biosciences (IGMS)
:IGMS
US Market

IGM Biosciences (IGMS) Price & Analysis

Compare
Followers

IGMS Stock Chart & Stats

$1.27
$0.00(0.00%)
--

IGM Biosciences News

IGMS FAQ

What was Igm Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Igm Biosciences’s market cap?
Currently, no data Available
When is Igm Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Igm Biosciences’s earnings last quarter?
Currently, no data Available
Is Igm Biosciences overvalued?
According to Wall Street analysts Igm Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Igm Biosciences pay dividends?
    Igm Biosciences does not currently pay dividends.
    What is Igm Biosciences’s EPS estimate?
    Igm Biosciences’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Igm Biosciences have?
    Currently, no data Available
    What happened to Igm Biosciences’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Igm Biosciences?
    Currently, no hedge funds are holding shares in IGMS
    What is the TipRanks Smart Score and how is it calculated?
    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

      Company Description

      Igm Biosciences

      IGM Biosciences, Inc. is a biotechnology company focused on developing innovative therapies based on its proprietary IgM antibody platform. Founded in 2010, the company operates primarily in the biopharmaceutical sector, concentrating on the design and commercialization of novel therapeutics for the treatment of various cancers and autoimmune diseases. Its core products include IGM-2323, an investigational IgM antibody designed to target specific cancer cells, as well as other pipeline candidates aimed at addressing unmet medical needs.

      Ownership Overview

      0.81%99.19%
      Insiders
      0.81%
      Mutual Funds
      ― Other Institutional Investors
      99.19% Public Companies and
      Individual Investors

      Options Prices

      Currently, No data available
      ---
      Popular Stocks